Get the Stockscreener App
4.295
0.59%
0.045
Aquestive Therapeutics Inc stock is traded at $4.295, with a volume of 1.79M.
It is up +0.59% in the last 24 hours and up +3.76% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$4.25
Open:
$4.22
24h Volume:
1.79M
Relative Volume:
0.76
Market Cap:
$538.44M
Revenue:
$50.27M
Net Income/Loss:
$-68.91M
P/E Ratio:
-7.1227
EPS:
-0.603
Net Cash Flow:
$-44.32M
1W Performance:
-0.35%
1M Performance:
+3.76%
6M Performance:
+10.18%
1Y Performance:
+4.01%
1-Day Range:
$4.20
$4.35
1-Week Range:
$4.015
$4.69
52-Week Range:
$2.93
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.29 | 533.42M | 50.27M | -68.91M | -44.32M | -0.603 |
TAK
Takeda Pharmaceutical Co Adr
|
17.36 | 56.30B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.45 | 42.85B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.585 | 42.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.72 | 30.49B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
506.95 | 21.43B | 3.17B | 1.29B | 1.01B | 27.09 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Resumed | Oppenheimer | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeut - The National Law Review
2026-08-16 | Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | NDAQ:AQST | Press Release - Stockhouse
Walleye Capital LLC Purchases New Stake in Aquestive Therapeutics, Inc. $AQST - marketbeat.com
Aquestive Therapeutics (NASDAQ:AQST) Lowered to "Sell" Rating by Wall Street Zen - marketbeat.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Wasatch Advisors LP Has $5.76 Million Position in Aquestive Therapeutics, Inc. $AQST - marketbeat.com
Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission - Sahm
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts - marketbeat.com
Aquestive Therapeutics Inc (AQST) (Q2 2026) Earnings Call Highlights: Anaphylm Resubmission on ... - Yahoo! Finance Canada
Aquestive Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Aquestive Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:AQST) 2026-08-12 - Seeking Alpha
Aquestive Therapeutics (NASDAQ:AQST) Shares Gap Down Following Weak Earnings - marketbeat.com
Aquestive Therapeutics Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Aquestive Therapeutics tops revenue views in Q2 2026 - Investing.com Canada
AQST: Q2 revenue up 38%, Anaphylm resubmission on track, and launch preparations advancing - TradingView
Aquestive Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Aquestive Therapeutics Q2 Loss Widens, Revenue Rises - Moomoo
Aquestive Plans to Take Epi Film Back to FDA with Positive Data - Allergic Living
Aquestive Therapeutics Latest Results: Sales guidance affirmed at $46-50M - scanx.trade
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Aquestive Therapeutics Announces Q2 2026 Financial Results and Investor Presentation - Kalkine Media
Aquestive Therapeutics (NASDAQ:AQST) Releases Earnings Results, Misses Expectations By $0.08 EPS - marketbeat.com
Aquestive Therapeutics: Q2 Earnings Snapshot - 10TV
Aquestive Therapeutics (AQST) grows revenue and refinances debt in Q2 2026 - Stock Titan
Aquestive Therapeutics Q2 revenue beats on Suboxone strength - TradingView
Aquestive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BRIEF-Aquestive Therapeutics, Inc. Q2 Revenue USD 13.819 Million Vs. IBES Estimate USD 11.4 Million - TradingView
Aquestive Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year of 2026 - marketscreener.com
Aquestive Therapeutics (NASDAQ:AQST) Shares Up 7.1%Here's Why - marketbeat.com
Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN) - The Globe and Mail
Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q2 2026 -- GF Value Sees 40% Downside - Yahoo Finance
Aquestive Therapeutics (NASDAQ:AQST): What Could Today’s Update Reveal About Regulatory Progress And Commercial Preparation? - Kalkine Media
Aquestive Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Form 8K Aquestive Therapeutics Inc For: 10 August By Investing.com - Investing.com Canada
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study - TradingView
Aquestive Therapeutics (NASDAQ:AQST) Shares Gap UpShould You Buy? - marketbeat.com
Anaphylm sublingual epinephrine film shows improved usability, comparable PK ahead of planned FDA resubmission - Contemporary Pediatrics
Aquestive Therapeutics Shares Rise After Positive Topline Results for Anaphylm Sublingual Film - Moomoo
Aquestive Therapeutics shares jump after encouraging Anaphylm study results - Yahoo Finance
Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q2 2026 -- GF Value Sees 35% Downside - GuruFocus
Aquestive Therapeutics' Potential Allergy Film Shows Improvements in Human Factors Study - marketscreener.com
Why is Aquestive Therapeutics stock surging today? By Investing.com - Investing.com Canada
Aquestive stock rises after Anaphylm study results By Investing.com - Investing.com Australia
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm Sublingual Film - Investing News Network
Aquestive reports study results for Anaphylm allergy treatment By Investing.com - Investing.com Australia
Aquestive Therapeutics releases Anaphylm human factors, clinical study presentation materials - Bitget
Aquestive reports study results for Anaphylm allergy treatment - Investing.com
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film - The Manila Times
Aquestive Reports Positive Human Factors and PK Results for Anaphylm, Plans NDA Resubmission Q3 2026 - TradingView
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aquestive Therapeutics Inc Stock (AQST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barber Daniel | President and CEO |
Jul 15 '26 |
Sale |
4.03 |
4,631 |
18,683 |
630,943 |
1.76%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):